Reuters logo
BRIEF-Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101
2017年8月29日 / 下午1点35分 / 24 天前

BRIEF-Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101

Aug 29 (Reuters) - Abeona Therapeutics Inc

* Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101 autologous cell therapy in Epidermolysis Bullosa

* Abeona Therapeutics Inc - company continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018 Source text for Eikon: Further company coverage: (Reporting by Sanjana Shivdas)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below